EP Patent

EP1534390A4 — 3'- (2Z) -1- (3,4-DIMETHYLPHENYL) -1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOLE-4-YLIDENE HYDRAZINO 2'-HYDROXY-1,1'- BIPHENYL -3 CARBON SOWING BIS (MONOETHANOLAMINE)

Assigned to GlaxoSmithKline LLC · Expires 2008-03-12 · 18y expired

What this patent protects

An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid.

USPTO Abstract

An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid.

Drugs covered by this patent

eltrombopag-olamine (ELTROMBOPAG OLAMINE)

Patent Metadata

Patent number: EP1534390A4
Jurisdiction: EP
Classification: —
Expires: 2008-03-12
Drug substance claim: No
Drug product claim: No
Assignee: GlaxoSmithKline LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.